Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001–2007)

Abi-said, 1997, The epidemiology of hematogenous candidiasis caused by different Candida species, Clin Infect Dis, 24, 1122, 10.1086/513663 Alexander, 2006, Contemporary tools for the diagnosis and management of invasive mycoses, Clin Infect Dis, 43, S15, 10.1086/504491 Bassetti, 2006, Epidemiological trends in nosocomial candidemia in intensive care, BMC Infect Dis, 6, 21, 10.1186/1471-2334-6-21 Boucher, 2004, Newer systemic antifungal agents-pharmacokinetics, safety and efficacy, Drugs, 64, 1997, 10.2165/00003495-200464180-00001 Colombo, 2006, Epidemiology of candidemia in Brasil: A nationwide sentinel surveillance of candidemia in eleven medical centers, J Clin Microbiol, 44, 2816, 10.1128/JCM.00773-06 Chakrabarti, 2009, Recent experience with fungaemia: Change in species distribution and azole resistance, Scand J Infect Dis, 41, 275, 10.1080/00365540902777105 Diomedi, 2004, Nuevos antifúngicos: Las equinocandinas, Rev Chil Infect, 21, 89, 10.4067/S0716-10182004000200001 Eggimann, 2003, Epidemiology of Candida species infections in critically ill non-immunosuppressed patients, Lancet Infect Dis, 3, 685, 10.1016/S1473-3099(03)00801-6 Fridkin, 2005, The changing face of fungal infections in health care setting, Clin Infect Dis, 41, 1455, 10.1086/497138 Gudlaugsson, 2003, Attributable mortality of nosocomial candidemia, Clin Infect Dis, 37, 1172, 10.1086/378745 Lee, 2000, Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984, Int J Antimicrob Agents, 16, 205, 10.1016/S0924-8579(00)00191-6 Leroy, 2009, Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006), Crit Care Med, 37, 1612, 10.1097/CCM.0b013e31819efac0 Mujica, 2004, Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clínicas. Período 1999–2001, Rev Arg Microbiol, 36, 107 National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeast. Approved guideline M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa 19087-1998. 2004;24:1-23. Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, 503, 10.1086/596757 Pfaller, 2006, Invasive fungal phatogens: Current epidemiological trends, Clin Infect Dis, 43, S3, 10.1086/504490 Pfaller, 2006, Correlation of MIC with outcome for Candida species tested against voriconazol: Analysis and proposal for interpretive breakpoints, J Clin Microbiol, 44, 819, 10.1128/JCM.44.3.819-826.2006 Pfaller, 2007, Epidemiology of invasive candidiasis: A persistent public health problem, Clin Microbiol Rev, 20, 133, 10.1128/CMR.00029-06 Pfaller, 2008, Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: A global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005, J Clin Microbiol, 43, 842, 10.1128/JCM.02122-07 Pfaller, 2008, Candida krusei, a multidrug-resistant opportunistic fungal pathogen: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program, J Clin Microbiol, 46, 515, 10.1128/JCM.01915-07 Sanglard, 2002, Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences, Lancet Infect Dis, 2, 73, 10.1016/S1473-3099(02)00181-0 St-Germain, 2001, Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canadá, J Clin Microbiol, 39, 949, 10.1128/JCM.39.3.949-953.2001